LLYEli Lilly and Company

Form 8-K (Items 2.02, 9.01) | Filed with the SEC on October 29, 2026 Current Price: $1,382.77 | Today's Change: +7.26%

---

What Happened

Eli Lilly and Company filed an 8-K with the SEC on October 29, 2026, disclosing its Q2 FY2026 financial results under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits). The company reported revenues of $28.286 billion for the quarter, alongside net income of $8.420 billion. Diluted earnings per share came in at $9.35, with basic EPS at $9.37 — representing a substantial profit margin relative to reported revenue.

---

Why It Matters

The scale of these numbers is notable in the context of the pharmaceutical sector. A quarterly revenue figure of $28.3 billion signals that Eli Lilly's commercial operations — including its high-profile incretin-class medicines — are generating cash at an extraordinary pace. A net income of $8.42 billion on that revenue base implies a net margin of approximately 29.8%, which is a strong indicator of operating leverage at this stage of the company's growth cycle. For investors, the key near-term takeaway is that the business is translating top-line growth into meaningful bottom-line expansion — a dynamic that was front of mind when StockWatch initiated coverage on September 24, 2026. The stock's move of +7.26% on the day of this report reflects the market's immediate reaction to these results.

---

Analysis

Several points stand out on closer examination:

• Revenue magnitude: $28.3 billion in a single quarter is a striking figure for a pharmaceutical company and suggests continued strong demand trajectory for Lilly's key franchises.
• Profit conversion: A net income of $8.42 billion against $28.3 billion in revenues reflects a business that has moved well past heavy reinvestment phases and is now generating significant free-cash-flow potential.
• EPS quality: Diluted EPS of $9.35 is meaningful both on an absolute basis and as a measure of per-share earnings power, particularly relevant for investors monitoring capital allocation and potential return of capital decisions.
• Stock reaction: The +7.26% move on the day suggests the market viewed these results as materially better than prevailing expectations — a gap-up of this magnitude in a large-cap name is rare and worth monitoring for sustainability.

Investors will want to watch for any management commentary on forward guidance, manufacturing capacity (a known constraint for incretin-class drugs), and pipeline milestones, none of which are quantified in the XBRL data from this filing but are likely to be covered in any accompanying earnings call or press release.

This filing follows StockWatch's existing initiated coverage. Readers are encouraged to review that published research for broader strategic context — a link is available on this page.

---

Disclaimer

This report is a news and informational summary of a publicly filed SEC disclosure. It does not constitute investment advice, a solicitation, or an offer to buy or sell any security. The structured financial figures cited are drawn exclusively from the official XBRL data associated with the referenced SEC filing. No rating or price target is issued or implied in this report. Past performance and reported results are not guarantees of future outcomes. Readers should conduct their own due diligence and consult a qualified financial adviser before making any investment decisions.

Existing Coverage

StockWatch has full coverage on LLY, published 2026-09-24. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-10-29. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/59478/000005947826000104/lly-20261029.htm